MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• MoonLake Immunotherapeutics (NASDAQ:MLTX) has received a consensus rating of "Moderate Buy" from analysts, with seven out of nine brokerages recommending to buy.
• The company's average 12-month price target is $74.43, with Goldman Sachs recently raising their price objective from $74.00 to $82.00.
• MoonLake's quarterly earnings report showed an EPS of ($0.87), which was lower than analysts' expectations of ($0.73).

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $74.4286.

A number of analysts have recently issued reports on MLTX shares. The Goldman Sachs Group raised their price objective on MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Wedbush reaffirmed an "outperform" rating and issued a $80.00 price objective (up from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Redburn Atlantic raised MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Rothschild & Co Redburn began coverage on MoonLake Immunotherapeutics in a report on Monday, July 28th. They set a "neutral" rating and a $65.00 price target for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $66.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th.

MoonLake Immunotherapeutics Stock Performance

MLTX opened at $55.89 on Monday. MoonLake Immunotherapeutics has a 12-month low of $31.42 and a 12-month high of $58.26. The stock has a market cap of $3.59 billion, a price-to-earnings ratio of -20.10 and a beta of 1.27. The business has a 50 day moving average of $50.51 and a 200-day moving average of $43.72. The company has a quick ratio of 16.65, a current ratio of 16.65 and a debt-to-equity ratio of 0.21.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same quarter in the prior year, the business earned ($0.39) earnings per share. On average, equities research analysts expect that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Institutional Trading of MoonLake Immunotherapeutics

Hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG lifted its holdings in MoonLake Immunotherapeutics by 59.8% during the 4th quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after purchasing an additional 338 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in MoonLake Immunotherapeutics during the 2nd quarter worth approximately $74,000. US Bancorp DE lifted its holdings in MoonLake Immunotherapeutics by 114.4% during the 1st quarter. US Bancorp DE now owns 2,208 shares of the company's stock worth $86,000 after purchasing an additional 1,178 shares during the last quarter. Quarry LP acquired a new stake in MoonLake Immunotherapeutics during the 1st quarter worth approximately $94,000. Finally, Advisors Asset Management Inc. lifted its holdings in MoonLake Immunotherapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company's stock worth $157,000 after purchasing an additional 1,803 shares during the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.